About Us Services Capabilities Facilities Careers News Notices Contact Us Swords Campus Home I About Us I History I Swords Campus Swords Campus: Site History .cls-1 { fill: url(#New_Gradient_Swatch_1); } .cls-2 { fill: url(#New_Gradient_Swatch_1-2); } .cls-3 { fill: url(#New_Gradient_Swatch_1-3); } .cls-4 { fill: none; stroke: #e6e7e8; stroke-miterlimit: 10; stroke-width: 2px; } .cls-5 { fill: #e51836; } .cls-6 { font-size: 22.4px; font-family: Muli-Black, Muli Black; } .cls-20, .cls-6 { fill: #fff; } .cls-7 { letter-spacing: -0.01em; } .cls-8 { letter-spacing: -0.01em; } .cls-9 { letter-spacing: 0.02em; } .cls-10 { fill: url(#New_Gradient_Swatch_1-4); } .cls-11 { fill: url(#New_Gradient_Swatch_1-5); } .cls-12 { fill: url(#New_Gradient_Swatch_1-6); } .cls-13 { fill: url(#New_Gradient_Swatch_1-7); } .cls-14 { fill: url(#New_Gradient_Swatch_1-8); } .cls-15 { fill: url(#New_Gradient_Swatch_1-9); } .cls-16 { fill: url(#New_Gradient_Swatch_1-10); } .cls-17 { fill: url(#New_Gradient_Swatch_1-11); } .cls-18 { fill: url(#New_Gradient_Swatch_1-12); } .cls-19 { fill: url(#New_Gradient_Swatch_1-13); } .cls-20 { font-size: 22.48px; font-family: Muli-ExtraBold, Muli ExtraBold; letter-spacing: 0.05em; } .cls-21 { font-size: 19.21px; } .cls-21, .cls-37 { fill: #231f20; font-family: Muli-Regular, Muli; } .cls-22 { letter-spacing: 0em; } .cls-23 { letter-spacing: 0.04em; } .cls-24 { letter-spacing: 0em; } .cls-25 { letter-spacing: -0.01em; } .cls-26 { letter-spacing: -0.01em; } .cls-27 { letter-spacing: 0em; } .cls-28 { letter-spacing: -0.01em; } .cls-29 { letter-spacing: 0em; } .cls-30 { letter-spacing: 0em; } .cls-31 { letter-spacing: 0em; } .cls-32 { letter-spacing: 0em; } .cls-33 { letter-spacing: -0.01em; } .cls-34 { letter-spacing: 0em; } .cls-35 { letter-spacing: 0em; } .cls-36 { letter-spacing: -0.02em; } .cls-37 { font-size: 19.91px; } .cls-38 { letter-spacing: -0.01em; } .cls-39 { letter-spacing: -0.01em; } .cls-40 { letter-spacing: 0em; } .cls-41 { letter-spacing: 0em; } .cls-42 { letter-spacing: 0em; } .cls-43 { fill: url(#New_Gradient_Swatch_1-14); } .cls-44 { letter-spacing: 0em; } .cls-45 { letter-spacing: -0.01em; } .cls-46 { letter-spacing: -0.01em; } .cls-47 { letter-spacing: 0em; } .cls-48 { letter-spacing: 0.01em; } .cls-49 { fill: url(#New_Gradient_Swatch_1-15); } .cls-50 { letter-spacing: 0em; } .cls-51 { letter-spacing: -0.08em; } .cls-52 { letter-spacing: 0em; } .cls-53 { letter-spacing: -0.03em; } year-map-about-svg Future Growth 2006 2012 2004 2005 LeadingHypertensionDrug #1 1964 Siteestablished LeadingHypertensionDrug #2 LeadingBreast CancerDrug LeadingHIV / AIDSDrug 2004/5 P4/P4AContainmentUpgrade toBand 5 $20M Official launch site for APIssince 2005 LeadingHepatitisB Drug LeadingChemotherapyDrug 2006/7 P7/P9Containment Upgradeto Band 4 $50MM LeadingDiabetesDrug #1 LeadingCardiovascularDrug 2010 Start ofPartnershipwith VEIS 2012HydrogeneratorUpgrade Project $20MM 2013 2018 LeadingHepatitis CDrug #1 2019 SK biotekIreland FutureGrowth 2018 - 2022 P3 Expansion 2020 SK biotek Irelandbecame an SK pharmteco company 2018 SK biotekTransition 2018 Today thesite has ~350 FTE’s DiabetesDrug #2 2007 2008 2009 2010 2011 1964 2003 Contact Us Today For Business Development & Marketing Enquires contact: skbiotekmarketing@sk.com For Recruitment Enquiries contact: skbtcareers@sk.com For Media and General Enquiries contact: skbiotekmarketing@sk.com CONTACT US SERVICES Development Analytical Research Services Process Development & Small Scale Manufacturing Validation & Commercial Launch Commercial Manufacture & Lifecycle Management Next Generation Chemistry Project Management COMPLIANCE SK biotek Ireland IP Policy Korea Intellectual Property Protection Policy Business with SK biotek Policy SK Korea Terms & Conditions SK biotek Ireland Purchasing T&Cs GDPR Policy Cookie Policy Copyright © 2021 by SK biotek. All Rights Reserved.